In this article for European Pharmaceutical Review, Adrian Toutoungi, Josef Fuss and Matt Caskie of Taylor Wessing explore how the novel coronavirus has hit the life sciences and biotech investment sector and how they see investors behaving as the lockdown and pandemic eases and develops over the next 24 months.
Read the full article first published in European Pharmaceutical Review in Issue #4 2020 on 25 August 2020.